Humacyte, Inc. (HUMA)
0.6939
+0.01
(+1.80%)
USD |
NASDAQ |
Aug 27, 16:00
0.7056
+0.01
(+1.69%)
After-Hours: 20:00
Humacyte Gross Profit Margin (Quarterly) : -423.2% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -423.2% |
| March 31, 2026 | -311.7% |
| December 31, 2025 | -2.23K% |
| September 30, 2025 | -182.2% |
| June 30, 2025 | -588.7% |
| March 31, 2025 | -282.8% |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 |
| Date | Value |
|---|---|
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | -6.50K% |
| June 30, 2022 | -56.19% |
| March 31, 2022 | -780.3% |
| December 31, 2021 | |
| September 30, 2021 | 0.00% |
| June 30, 2021 | -131.9% |
| March 31, 2021 | -903.2% |
| December 31, 2020 | |
| September 30, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Amgen, Inc. | 72.08% |
| Altimmune, Inc. | -- |
| Protalix Biotherapeutics, Inc. | 60.99% |
| Taysha Gene Therapies, Inc. | -- |
| Agenus, Inc. | 98.50% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.07K% |
| Return on Assets | -81.25% |
| Return on Invested Capital | -128.5% |
| Profit Margin (Quarterly) | -9.06K% |
| Operating Margin (Quarterly) | -6.65K% |
| Return on Net Operating Assets | -169.3% |